Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 3/20 | 0.58 |
| ▸ | KIT | P10721 | 5/20 | 0.54 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 3/20 | 0.43 |
| ▸ | ITK | Q08881 | 3/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.41 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4831608 | 0.91 | MAPK8 (0.53) | NTRK1KITMAPK8MAPK9MAPK10 | |
| SCHEMBL4829456 | 0.88 | NTRK1 (0.46) | NTRK1KITMAPK8MAPK9MAPK10 | |
| SCHEMBL4831294 | 0.87 | AXL (0.56) | NTRK1MAPK9BTKMAP3K11AXL | |
| SCHEMBL4831086 | 0.85 | KIT (0.61) | NTRK1KITCCNT1CCNA2CDK2 | |
| SCHEMBL4831469 | 0.85 | CDC7 (0.46) | NTRK1KITBTKITKCCNT1 | |
| SCHEMBL4298090 | 0.83 | DYRK1A (0.53) | NTRK1KITCCNT1CCNA2CDK2 | |
| SCHEMBL4827463 | 0.83 | SGK1 (0.45) | NTRK1KITMAPK8MAPK9MAPK10 | |
| SCHEMBL4832683 | 0.83 | MAPK1 (0.44) | NTRK1KITCCNT1CCNA2CDK2 | |
| SCHEMBL4827652 | 0.83 | NEK1 (0.45) | NTRK1KITMAPK9BTKITK | |
| SCHEMBL4827380 | 0.83 | NTRK1 (0.50) | NTRK1KITCCNT1CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306126-A1 | Indole Derivatives | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| US-7446199-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-04 | — | — | US | disclosed |
| US-7446199-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-04 | — | — | US | disclosed |
| US-7446199-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-04 | — | — | US | disclosed |
| EP-1664043-B1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2007-11-14 | — | — | EP | disclosed |
| US-20050137201-A1 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137201-A1 | Compositions useful as inhibitors of protein kinases | MAP3K20, PACSIN2, MAP3K6 | NTRK1 1926/4885KIT 1325/4885MAPK8 226/4885 |
| US-20090306126-A1 | Indole Derivatives | MTOR, IDO1, AKT1S1 | NTRK1 942/4885KIT 322/4885MAPK8 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.